SAN.PA - Sanofi
| Previous Close | 75.12 |
| Open | 74.97 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 74.24 - 75.33 |
| 52 Week Range | 62.88 - 86.39 |
| Volume | 2,747,102 |
| Avg. Volume | 2,293,969 |
| Market Cap | 92.465B |
| Beta | 0.68 |
| PE Ratio (TTM) | 27.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.03 (4.01%) |
| Ex-Dividend Date | 2018-05-11 |
| 1y Target Est | N/A |
- Market Realist•6 hours ago
A Look at Shire’s Valuation on September 19
Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.
- Zacks•14 hours ago
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
- Reuters•3 days ago
Sanofi pledges to keep up its restructuring efforts
Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (£1.3 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.
- Reuters•3 days ago
Sanofi pledges to keep up its restructuring efforts
Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. The French drugmaker, hurt by declining revenue at its diabetes business in recent years, is eyeing a return to growth from the second half of 2018 as it builds upon acquisitions made earlier this year. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday.
- Zacks•3 days ago
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.
- Market Realist•6 days ago
Analyzing uniQure’s Valuation Trend
Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.
- Insider Monkey•6 days ago
5 Problematic Stocks Francis Chou Dared To Buy
Francis Chou, a well-regarded Canadian value investor, the founder of Chou Associates Management, and Morningstar Fund Manager of the Decade in 2004, was once just an ordinary immigrant in Canada with $200 in his pocket. Even though he is Chinese, he was born and raised in India, and came to Canada looking for a job. For […]
Reuters•7 days agoSanofi pledges to keep up its restructuring efforts
Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (1.33 billion pounds) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.
- Reuters•7 days ago
Sanofi pledges to keep up its restructuring efforts
Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. The French drugmaker, hurt by declining revenue at its diabetes business in recent years, is eyeing a return to growth from the second half of 2018 as it builds upon acquisitions made earlier this year. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday.
Reuters•8 days agoBayer's pharma unit head Weinand quits to join Sanofi
Bayer, which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs. In a statement on Thursday, Germany's Bayer said Weinand would be succeeded by Stefan Oelrich, currently a member of Sanofi's executive committee in charge of diabetes and cardiovascular businesses. For Bayer, the job swap comes in the midst of talk on job cuts and outsourcing as part of a review of its drug research and development operations, which investors say has produced few promising products.
Reuters•8 days agoBayer's pharma unit head Weinand quits to join Sanofi
Bayer (BAYGn.DE), which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi (SASY.PA) to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs. In a statement on Thursday, Germany's Bayer said Weinand would be succeeded by Stefan Oelrich, currently a member of Sanofi's executive committee in charge of diabetes and cardiovascular businesses. For Bayer, the job swap comes in the midst of talk on job cuts and outsourcing as part of a review of its drug research and development operations, which investors say has produced few promising products.
- The Wall Street Journal•8 days ago
[$$] Sanofi Poaches Bayer Manager to Lead Unit
Sanofi hired the head of Bayer’s pharmaceuticals division to lead its Primary Care unit, one of two new divisions that the French company is creating.
- Bloomberg•8 days ago
Sanofi and Bayer Are Swapping Executives
Sanofi and Bayer AG, two European drugmakers with blockbuster medicines facing headwinds, are swapping top executives. Sanofi is bringing in Bayer’s Dieter Weinand as executive vice president in charge of a new unit that combines its diabetes and cardiovascular operations with a broader group of established products, the Paris-based company said in a statement Thursday. At the same time, Stefan Oelrich, head of diabetes at Sanofi, will replace Weinand as the head of Bayer’s pharmaceuticals division in November.
- Motley Fool•8 days ago
3 Top Value Stocks to Buy Right Now
This power-packed list of value stocks from diverse industries is all you need to see right now.
- Benzinga•10 days ago
BofA Upgrades Sanofi, Names 3 Growth Drivers For Pharma Stock
Sanofi SA (ADR) (NYSE: SNY ), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical ...
- Zacks•13 days ago
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
Market Realist•15 days agoWhy Sangamo Therapeutics Stock Is Down More than 22% Today
Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. The stock is sliding after the company announced the results of its Phase 1/2 study data for its gene editing candidate SB-913. Sangamo Therapeutics had announced that it would release the results of its Champion study of SB-913 on August 30.
- The Wall Street Journal•16 days ago
[$$] Sanofi Pays $25 Million to Settle Bribery Charges
The alleged schemes spanned multiple countries and involved bribes to government procurement officials and health-care providers to receive tenders and increase prescriptions of the company’s products, the SEC said. The alleged payments violated the Foreign Corrupt Practices Act, which bars bribes of foreign officials for business purposes, the SEC said. The SEC said Sanofi violated the books-and-records and internal-control provisions of the FCPA.
Reuters•16 days agoSanofi to pay more than $25 million to resolve corruption charges: SEC
French pharmaceutical giant Sanofi will pay more than $25 million to settle charges that its Kazakhstan and Middle East subsidiaries made corrupt payments to win business, the top U.S. securities regulator ...
- Zacks•18 days ago
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.
- Reuters•18 days ago
Sanofi wins European approval for rare blood-clotting disorder treatment
French drugmaker Sanofi on Monday said it had secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in June had recommended the approval of caplacizumab, which is to be prescribed to adults suffering acquired thrombotic thrombocytopenic purpura (aTTP). The U.S Food & Drug Administration (FDA), which has granted the drug a 'Fast Track' designation, is expected to follow suit in early 2019.
- Simply Wall St.•21 days ago
Is Sanofi (EPA:SAN) Attractive At This PE Ratio?
This article is intended for those of you who are at the beginning of your investing journey and want to learn about the link between company’s fundamentals and stock marketRead More...
- Market Realist•22 days ago
Estimates and Recommendations for Novartis in August
Wall Street analysts are estimating that Novartis will report revenues of $52.4 billion during 2018, a 6.7% growth year-over-year compared to $49.1 billion during 2017. Analysts are estimating that its net income margin will decrease to 23% during 2018 compared to 23.2% during 2017, mainly due to an increase in overall selling, general, and administrative expenses and increased research and development expenses. Novartis stock has increased ~0.7% over the last 12 months and ~0.2% in 2018 year-to-date.
- Zacks•22 days ago
The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross
The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross
- Market Realist•22 days ago
European Commission Approves Novartis’s Tafinlar/Mekinist Combo
Novartis (NVS) announced on August 29 that the European Commission had approved the combination of its drugs Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of patients with stage III BRAF V600 mutation-positive melanoma. This was the third approval in Europe for the Tafinlar and Mekinist combination for the treatment of various tumor types.
